Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cabaletta Bio, Inc.NASDAQ: CABA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.94M fell 14.5% year over year, behind the -5.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +25.8% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +5.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.94M+8.2% QoQ
- Last fiscal yearDec 2025
- $29.57M+5.8% YoY
- LTMMar 2026
- $28.39M-5.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -14.5% | -100.0% | -85.5 pp |
| 1 year | +5.8% | -100.0% | -105.8 pp |
| 3-year CAGR | +25.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 29.57M USD
- Year-over-year change
- +5.8%
- 4-year CAGR
- +20.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.57M | +5.8% |
| FY2024 | 2024-12-31 | 27.94M | +45.2% |
| FY2023 | 2023-12-31 | 19.24M | +29.6% |
| FY2022 | 2022-12-31 | 14.84M | +7.4% |
| FY2021 | 2021-12-31 | 13.82M | — |
Selling, General & Admin vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.3% is the 5th highest of 11, against a peer median of -10.7%.
- Over three fiscal years its annual growth of +25.8% compares with a peer median of -1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.88M USD | -11.2% | -10.5% | — | |
| LTM Mar 2026 | $46.76M USD | -29.2% | -11.0% | 120.9% | |
| LTM Mar 2026 | $40.64M USD | -22.7% | -27.3% | 131109.7% | |
| LTM Mar 2026 | $37.43M USD | +18.7% | +65.2% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M USD | -13.0% | +55.9% | — |
| LTM Mar 2026 | $30.28M USD | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $28.39M USD | -5.3% | +25.8% | — | |
| LTM Mar 2026 | $27.31M USD | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $26.76M USD | +58.7% | +29.7% | — | |
| LTM Mar 2026 | €14.33M EUR | +6.6% | -8.9% | 106.6% | |
| FY2025 | A$8.64M AUD | -2.4% | +6.2% | 171.4% | |
| Peer median (excluding CABA) | — | -10.7% | -1.3% | 171.4% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.